Correlation Engine 2.0
Clear Search sequence regions


  • case (3)
  • humans (1)
  • patient (1)
  • platelets (2)
  • prostacyclin (8)
  • thrombosis (2)
  • Sizes of these terms reflect their relevance to your search.

    Prostacyclin and analogues are successfully used in the treatment of pulmonary arterial hypertension (PAH) due to their vasodilatory effect on pulmonary arteries. Besides vasodilatory effect, prostacyclin analogues inhibit platelets, but their antiplatelet effect is not thoroughly established. The antiplatelet effect of prostacyclin analogues may be beneficial in case of increased risk of thromboembolic events, or undesirable in case of increased risk of bleeding. Since prostacyclin and analogues differ regarding their potency and form of administration, they might also inhibit platelets to a different extent. This review summarizes the recent evidence on the antiplatelet effects of prostacyclin and analogue in the treatment of PAH, this is important to consider when choosing the optimal treatment regimen in tailoring to an individual patients' needs.

    Citation

    Sylwester P Rogula, Hubert M Mutwil, Aleksandra Gąsecka, Marcin Kurzyna, Krzysztof J Filipiak. Antiplatelet effects of prostacyclin analogues: Which one to choose in case of thrombosis or bleeding? Cardiology journal. 2021;28(6):954-961

    Expand section icon Mesh Tags

    Expand section icon Substances


    PMID: 33200814

    View Full Text